Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rosiglitazone: trials, tribulations and termination.

× No keyword cloud information.

33 in total

Review 1. Thiazolidinediones.

Authors: Hannele Yki-Järvinen
Journal: N Engl J Med Date: 2004-09-09 Impact factor: 91.245

Review 2. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.

Authors: Bianca Hemmingsen; Søren S Lund; Jørn Wetterslev; Allan Vaag
Journal: Eur J Endocrinol Date: 2009-04-15 Impact factor: 6.664

Review 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors: Andrew J Krentz; Clifford J Bailey
Journal: Drugs Date: 2005 Impact factor: 9.546

Review 4. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors: Steven E Nissen; Kathy Wolski
Journal: Arch Intern Med Date: 2010-07-26

Review 5. Hyperinsulinemia and atherosclerosis.

Authors: R W Stout
Journal: Diabetes Date: 1996-07 Impact factor: 9.461

Review 6. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Authors: Andrew Krentz
Journal: Diabetes Metab Res Rev Date: 2009-02 Impact factor: 4.876

7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

9. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal: Lancet Date: 2009-06-06 Impact factor: 79.321

10. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors: Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu
Journal: JAMA Date: 2008-03-31 Impact factor: 56.272

4 in total

Rosiglitazone: trials, tribulations and termination.